A press conference in the Oval Office was interrupted when a drug executive fainted while President Donald Trump was announcing a deal aimed at reducing obesity drug prices.
During the event on Thursday, a drug executive believed to be Gordon Findlay, the global brand director for Novo Nordisk, suddenly collapsed. This happened as President Trump and representatives from drugmakers were discussing new agreements with Eli Lilly and Novo Nordisk to expand coverage and lower prices for obesity treatments Zepbound and Wegovy.
"Are you okay? Gordon, are you okay?"
About 30 minutes later, the press conference resumed with President Trump providing an update on the executive’s condition.
The man was identified as Gordon Findlay, the global brand director for Novo Nordisk.
Author's summary: During a high-profile press conference on lowering obesity drug prices, Novo Nordisk’s Gordon Findlay unexpectedly collapsed, prompting swift medical assistance and a brief pause before the event continued.